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receptors have also been examined thus 
far. However, even these studies could 
not draw a definite conclusion.
Recent development in the SNP typ-
ing technology and collation of informa-
tion regarding linkage disequilibrium 
in the human genome have facilitated 
GWAS and candidate gene analyses in 
a large number of subjects by using tag-
ging SNPs that can completely cover the 
gene or locus of interest. Because, in the 
case of common genetic variations, the 
genotype-specific differences in bio-
logical functions are expected to be 
very small, an appropriate association 
study such as that conducted by Ng et 
al.1 with a sufficient number of subjects, 
probably several thousand case and con-
trol subjects, should be performed for 
each candidate gene before evaluation 
of the functional significance of genetic 
variations.
Inflammatory cytokine genes might 
be good candidates for genes that confer 
susceptibility to diabetic nephropathy. 
Moreover, well-organized approaches, 
such as GWASs for diabetic nephrop-
athy, are being conducted in several 
independent populations; a conclusion 
regarding the susceptibility genes for 
diabetic nephropathy may be drawn in 
the near future. 
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chronic kidney disease (CKD)? Gender differences in the prevalence and 
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Women live longer than men. Can this 
phenomenon be explained by chronic 
kidney disease (CKD)? Proteinuria is 
a known risk factor for cardiovascular 
disease (CVD) and mortality. Recently, a 
low estimated glomerular filtration rate 
(eGFR) per se has also become widely 
accepted as a risk factor for CVD and 
mortality.1 The high incidence of infec-
tion and malignancies in the elderly pop-
ulation may be, in part, due to CKD. The 
mortality rate increases with a decline in 
glomerular filtration rate (GFR) and is 
highest among patients with end-stage 
renal disease (ESRD). Therefore, an esti-
mation of GFR is recommended among 
patients with CVD. In such patients, 
serum creatinine should be examined to 
determine the eGFR. The World Health 
Organization now considers kidney dis-
ease a major chronic disease.
CKD is defined as either kidney dam-
age indicated by urine, imaging, and 
histologic findings, or a low eGFR, less 
than 60 ml/min/1.73 m2, for more than 
3 months. GFR is calculated by either the 
Modification of Diet in Renal Disease 
(MDRD) Study equation or the Cock-
croft–Gault formula. The concept of CKD 
was developed to educate physicians and 
the general public in the prevention of 
ESRD and other related medical compli-
cations. The mechanisms underlying the 
increased risk of CVD in CKD patients, 
however, are not well understood. In 
addition to the conventional risk factors 
for CVD, CKD patients often have associ-
ated non-conventional risk factors such as 
volume expansion, sympathetic overactiv-
ity, sleep disturbance, hypoxia, increased 
oxidative stress, dyslipidemia, anemia, 
and serum calcium and phosphate 
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disturbances, which are proportional 
to the decline in GFR. ESRD patients, 
therefore, have multiple risk factors to be 
corrected. Trials toward the treatment of 
any single risk factor—for example, cor-
rection of anemia and high low-density 
lipoprotein cholesterol—have failed to 
show an improvement in CKD patient 
survival. CVD remains the main cause 
of death among ESRD patients. These 
observations suggest the importance of 
early detection of and early intervention 
in CKD, preferably at stages 1–3.
Gender differences have been docu-
mented in the field of nephrology. Women 
seem to be somewhat protected from 
developing ESRD.2 The cumulative inci-
dence of ESRD remains low during the 
reproductive ages and begins to rise 10 
years later in women than in men among 
participants in community-based screen-
ings (Figure 1).2 A nationwide survey of 
ESRD by the Japanese Society for Dialysis 
Therapy revealed a higher incidence and 
prevalence in men than in women. Fur-
ther, the mean age at the start of dialysis is 
also higher in women than in men.
The natural course of CKD progres-
sion is largely unknown. CKD is often 
asymptomatic, and late referral to neph-
rologists, defined as referral within 6–12 
months of starting dialysis, is common. 
CKD, however, often develops in those 
with conventional risk factors for athero-
sclerosis, such as hypertension, diabetes 
mellitus, hyperlipidemia, and a history 
of CVD. We identified screening par-
ticipants who later entered a dialysis 
program and found that dipstick-pos-
itive proteinuria and hypertension are 
important predictors of developing 
ESRD.2 Lifestyle-related factors that 
are often associated with obesity and 
metabolic syndrome may also have a 
role in the development and progres-
sion of CKD. The obesity-related risk of 
developing proteinuria is independent of 
that of hypertension and diabetes mel-
litus. Smoking may accelerate kidney 
damage in patients with metabolic syn-
drome. Among the lifestyle-related fac-
tors, smoking and excess alcohol intake 
are known risk factors for CKD. Mod-
erate alcohol intake, less than 20 g per 
day, however, decreases the risk of CKD. 
There is a protective effect of weight loss 
on CKD progression and proteinuria 
reduction prior to progression to ESRD.
Kidney function deteriorates with 
aging. The extent of an age-related GFR 
decline, however, differs between ethnic 
groups and sexes. Longitudinal studies in 
the United States3 and Norway4 revealed a 
decline in GFR of 0.75–1.03 ml/min/1.73 
m2 per year. In the general Japanese popu-
lation, the average GFR decline is 0.36 ml/
min/1.73 m2 per year. GFR has declined 
at a similar rate in men and women in all 
age groups.5 Others have reported that 
one-third of normal individuals showed 
no change in creatinine clearance in a 
20-year longitudinal study.6 Halbesma et 
al.7 (this issue) report that there are gen-
der differences: –0.33 (women) and –0.55 
(men) ml/min/1.73 m2 per year, based on 
the relatively new method of ‘slope-based 
analysis’ rather than ‘threshold analysis.’ 
They compared the age-related changes 
in kidney function based on recipro-
cal serum creatinine (1/SCr) and the 
MDRD Study equation. The evaluation 
of a decline in GFR is not accurate with 
the use of the MDRD Study formula, par-
ticularly in those with eGFR greater than 
60 ml/min/1.73 m2 or in those with obes-
ity, and results in an under estimation of 
GFR in those with normal renal function. 
It is also not suitable for evaluating long-
term changes in GFR, as people may lose 
muscle mass with aging.
Among the risk factors for GFR decline, 
proteinuria, including microalbuminuria, 
is a strong predictor of GFR decline. Low 
GFR per se, which is often observed in the 
elderly population, is not a strong predic-
tor of developing ESRD if not otherwise 
associated with proteinuria. In the study by 
Halbesma et al.,7 systolic blood pressure in 
women was 10 mm Hg lower than in men. 
Blood pressure is a major determinant 
of atherosclerosis and developing ESRD; 
therefore, the gender difference in systolic 
blood pressure may contribute to the slower 
decline in GFR in women. Other plausible 
explanations for the gender differences in 
GFR decline include hormonal status and 
lifestyle differences, such as dietary protein 
intake, salt, smoking, and alcohol intake. 
On the basis of their report, Halbesma et 
al.7 rule out the possible role of diet based 
on the estimated amount of protein intake 
shown by urine urea nitrogen excretion 
and salt intake. The prevalence and impact 
of metabolic syndrome, which is related to 
the development of CKD, may also con-
tribute to the gender difference in the age-
related decline in GFR. Obesity induces a 
state of hyperfiltration, which, if continued 
for a certain period, can cause a decline in 
GFR, as in diabetic nephropathy.
figure 1 | The cumulative incidence of ESRD per 100,000 screenees, shown by age at 
screening in both men and women. Figure was created from database of ref. 2.
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Baseline GFR differs among sex, age, 
and ethnic groups. The prevalence of 
CKD is increasing, particularly in those 
of age 70 and over in the United States8 
and in Japan (the Hisayama study).9 The 
prevalence of CKD has doubled in both 
men and women from 1974 to 2002 
(T. Ninomiya, personal communication). 
The prevalence of CKD is expected to 
increase, particularly in the elderly popu-
lation. They may survive after CVD and 
are then exposed to multiple CKD pre-
dictors, such as smoking, metabolic syn-
drome, obesity, and multiple nephrotoxic 
substances. As a whole, the prevalence of 
CKD will probably increase with the grow-
ing elderly population. Subjects with low 
birth weight, which is a predictor of low 
nephron number, develop insulin resist-
ance and therefore have an increased risk 
for both CKD and ESRD.
Multidisciplinary collaboration among 
physicians, health-care workers, and 
governments is necessary to halt the pro-
gression of CKD. The incidence of ESRD 
is increasing worldwide despite several 
strategies, including universal or targeted 
screening and new drugs.10 More attention 
must be focused on the early detection of 
CKD, particularly in the elderly popula-
tion and in those with obesity, metabolic 
syndrome, hypertension, or diabetes mel-
litus. Further studies on the gender differ-
ences in GFR decline may supply another 
tool toward the prevention of CKD.
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